NCT02170987已完成1 期
Assessment of Electrophysiological Effects of 150 mg and 600 mg of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind Three-way Crossover Study With an Open Label Positive Control (Moxifloxacin)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 主要终点
- Change from baseline in mean time-matched QTc Interval
研究概览
简要总结
To investigate if dabigatran has a clinically relevant impact on the cardiac electrophysiology that is manifest as prolongation in QT-interval.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy female (at least 1/3) and male (at least 1/3) volunteers as determined by the results of screening according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (BP, HR), 12-lead ECG, clinical laboratory tests
- •Age >= 18 and Age <= 65 years
- •BMI >= 20.0 and BMI <=29.9 kg/m2 (Body Mass Index)
- •Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation
排除标准
- •Any finding of the medical examination (including BP, pulse rate (PR) and ECG) deviating from normal and of clinical relevance
- •Any evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
- •Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- •Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- •Participation in another trial with an investigational drug within two months prior to administration or during the trial
- •Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- •Inability to refrain from smoking on trial days
- •Alcohol abuse (more than 60 g/day)
- •Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- •History of any bleeding disorder or acute blood coagulation defect
- •Hypersensitivity to moxifloxacin and/or related drugs of this class
- •Excessive physical activities (within one week prior to administration or during the trial)
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of study centre
- •History of additional risk factors for Torsade des Pointes (e.g. heart failure, hypokalemia, family history of long QT syndrome)
- •Any screening ECG value outside of the reference range of clinical relevance including, but not limited to heart rate of >80 bpm or <45 bpm, PR interval >220 ms, QRS interval >120 ms, QT interval >470 ms or QTcB or QTcF >450 ms
- •For female subjects:
- •Positive pregnancy test
- •No adequate contraception e.g. oral contraceptives, sterilisation, intrauterine device (IUD)
- •Inability to maintain this adequate contraception during the whole study period
- •Lactation period
研究组 & 干预措施
Dabigatran etexilate low
Experimental
干预措施: Dabigatran etexilate low (Drug)
Dabigatran etexilate high
Experimental
干预措施: Dabigatran etexilate high (Drug)
Placebo to dabigatran etexilate
Placebo Comparator
干预措施: Placebo (Drug)
Moxifloxacin
Active Comparator
干预措施: Moxifloxacin (Drug)
结局指标
主要结局
Change from baseline in mean time-matched QTc Interval
时间窗: at 1.5, 2, and 3 hours following administration
次要结局
- Mean of the QTcI values of all ECGs(from 1 to 6 hours following administration)
- Change from baseline of the QTcI(from 1 to 24 hours following administration)
研究者
相似试验
已完成
不适用
Does dapagliflozin change heart function as detected by ultrasound in patients with heart failure?Heart failure and reduced ejection fractionCirculatory SystemISRCTN95382621Mouloud Mammeri University of Tizi-Ouzou43
已完成
不适用
Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction PatientsMyocardial Remodeling, VentricularMyocardial InfarctionDiabetes Mellitus, Type 2NCT05335629Ain Shams University54
已完成
1 期
Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With DabigatranHealthyNCT01595854Boehringer Ingelheim36
终止
2 期
Dabigatran Etexilate in Patients With Mechanical Heart ValvesHeart Valve DiseasesNCT01452347Boehringer Ingelheim328
招募中
2 期
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKDChronic Kidney DiseasesNCT05359263Tor Biering-Sørensen222